PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-108.36%
Negative EBIT growth while Healthcare median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-9873.13%
Negative operating income growth while Healthcare median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-16129.65%
Negative net income growth while Healthcare median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-12933.18%
Negative EPS growth while Healthcare median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-12933.18%
Negative diluted EPS growth while Healthcare median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
24.22%
Share change of 24.22% while Healthcare median is zero. Walter Schloss would see if the modest difference matters long-term.
24.22%
Diluted share change of 24.22% while Healthcare median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
-18.12%
Negative OCF growth while Healthcare median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
0.96%
FCF growth of 0.96% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.71%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-63.71%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-2899.60%
Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-30244.22%
Negative 10Y net income/share CAGR vs. Healthcare median of 29.38%. Seth Klarman might see a fundamental problem if peers maintain growth.
-30244.22%
Negative 5Y CAGR while Healthcare median is 19.13%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-27789.91%
Negative 3Y CAGR while Healthcare median is 13.23%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
-195.85%
Negative 10Y equity/share growth while Healthcare median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-195.85%
Negative 5Y equity/share growth while Healthcare median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
20.77%
3Y equity/share CAGR of 20.77% while Healthcare median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.33%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
14.08%
BV/share growth of 14.08% while Healthcare is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
11.04%
Debt growth of 11.04% while Healthcare median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
35.15%
R&D growth of 35.15% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
3110.63%
SG&A growth of 3110.63% while Healthcare median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.